BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26235264)

  • 1. Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings.
    Kawahara A; Fukumitsu C; Taira T; Abe H; Takase Y; Murata K; Yamaguchi T; Azuma K; Ishii H; Takamori S; Akiba J; Hoshino T; Kage M
    Cancer Cytopathol; 2015 Oct; 123(10):620-8. PubMed ID: 26235264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
    Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
    Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.
    Khode R; Larsen DA; Culbreath BC; Parrish S; Walker KL; Sayage-Rabie L; Beissner RS; Rao A
    Cancer Cytopathol; 2013 Jul; 121(7):361-9. PubMed ID: 23364874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
    Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
    Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.
    Shingyoji M; Kageyama H; Sakaida T; Nakajima T; Matsui Y; Itakura M; Iuchi T; Yokoi S; Kimura H; Iizasa T
    J Thorac Oncol; 2011 Jul; 6(7):1215-20. PubMed ID: 21610522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.
    Mitiushkina NV; Iyevleva AG; Poltoratskiy AN; Ivantsov AO; Togo AV; Polyakov IS; Orlov SV; Matsko DE; Novik VI; Imyanitov EN
    Cancer Cytopathol; 2013 Jul; 121(7):370-6. PubMed ID: 23408463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of EGFR mutation analysis for small microdissected cytological specimens using multitech DNA extraction solution.
    Oh SY; Lee HT
    Cancer Cytopathol; 2015 Jul; 123(7):401-12. PubMed ID: 25964184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
    Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
    J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
    Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
    Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
    Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
    Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.
    Hubers AJ; Heideman DA; Yatabe Y; Wood MD; Tull J; Tarón M; Molina MA; Mayo C; Bertran-Alamillo J; Herder GJ; Koning R; Sie D; Ylstra B; Meijer GA; Snijders PJ; Witte BI; Postmus PE; Smit EF; Thunnissen E
    Lung Cancer; 2013 Oct; 82(1):38-43. PubMed ID: 23927883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Okamoto T; Kohno M; Ito K; Takada K; Katsura M; Morodomi Y; Toyokawa G; Shoji F; Maehara Y
    Anticancer Res; 2017 Apr; 37(4):1729-1735. PubMed ID: 28373435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
    Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas.
    Sun PL; Jin Y; Kim H; Lee CT; Jheon S; Chung JH
    Cancer Cytopathol; 2013 Jun; 121(6):311-9. PubMed ID: 23225576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-efficiency EGFR genotyping using cell-free DNA in bronchial washing fluid.
    Murata Y; Nakajima Y; Sato Y; Hizawa N; Yamakawa D; Matsubara D; Noguchi M; Minami Y
    Jpn J Clin Oncol; 2024 Jun; 54(6):681-688. PubMed ID: 38476004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.
    Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Kobayashi N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
    J Thorac Oncol; 2012 Sep; 7(9):1369-81. PubMed ID: 22858585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.